Omodenbamab (514-G3) is a humanised monoclonal antibody (Kd = 0.0467 nM) that neutralises SpA (Staphylococcus Protein A), acting by targeting SpA on the cell wall of S. aureus, and can be used for S. aureus bloodstream infections.

Methods:
Human blood cells were treated with 10 μg/mL Omodenbamab and incubated for 30 minutes, 1.5 hours, and 2.5 hours to evaluate its effect on the opsonophagocytic activity against S. aureus.
Results:
Omodenbamab significantly enhanced the opsonophagocytic activity of human blood cells against S. aureus. [1]

Methods:
In a Balb/C mouse model of MRSA bacteremia, Omodenbamab was administered via intravenous injection at doses of 2.5 mg/mouse and 10 mg/mouse.
Results:
Omodenbamab increased survival in Balb/C mice within the MRSA bacteremia model. [1]

Human

Monoclonal

Unconjugated